Brief: PureTech Health Says LYT-200 Shows Favorable Tolerability And Efficacy In Phase 1b Trial
05/12/2025 19:08
Dec 5 (Reuters) - PureTech Health PLC PRTC.L: PURETECH’S FOUNDED ENTITY GALLOP ONCOLOGY ANNOUNCES POSITIVE INITIAL TOPLINE DATA FROM PHASE 1B TRIAL OF LYT-200 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME PURETECH HEALTH - LYT-200 SHOWS FAVORABLE TOLERABILITY AND EFFICACY IN PHASE 1B TRIAL Source text: ID:nBwbLQQRNa Further company coverage: PRTC.L ((Reuters.Briefs@thomsonreuters.com;))